Regulatory B and T Cells and Their Association With Clinical Response in New-Onset Lupus Nephritis Patients

Girimaji, Niveditha; Kaundal, Urvashi; Rathi, Manish; Sharma, Aman; Nada, Ritambhra; Ramachandran, Raja; Rakha, Aruna; Gupta, Krishan Lal

doi:10.1016/j.ekir.2020.04.019

Cited by 3 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following immunosuppression in responders, Breg populations increased. In contrast, no noticeable change was seen in non-responders [19] .…”

Section: Discussionmentioning

confidence: 70%

“…The proportion of Bregs in LN patients and daily steroid dose were found to be negatively correlated by Heinemann et al [1] . Also recently Girimaji et al [19] reported that after six months of immunosuppression initiation, Bregs in LN patients become comparable to HC with no significant difference between them. This finding was observed in all cases irrespective of the type of immunosuppression received by the studied cases.…”

Section: Discussionmentioning

confidence: 93%

“…Lupus nephritis is a serious and common presentation of SLE that is linked to substantial morbidity and mortality [18] . B-lymphocytes cells are pathogenic in the majority of autoimmune disorders as they generate autoantibodies [19] . Recent researches have focused on Breg as a crucial functioning subset of B cells that has a vital capacity in suppressing the autoimmune response and have been widely studied in many autoimmune disorders including vasculitis, rheumatoid arthritis, multiple sclerosis, and SLE [20][21][22][23] .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Circulating CD19 CD24hi CD38hi Regulatory B Cells Percentage in Lupus Nephritis Patients: Does It Differ?

Fathi¹,

Gamal²,

Shawky³

et al. 2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: There is a debate about the functional role of regulatory B cells in the lupus nephritis (LN) pathogenesis. Objective:The aim of the present study was to analyze total B lymphocytes and their subtype regulatory B lymphocytes (Breg) % in systemic lupus erythematous (SLE) patients, in addition to assess their association with LN activity. Patients and Methods:The present study included 19 lupus nephritis (LN) patients, 11 SLE patients without lupus nephritis (non-LN). They were matched with 20 healthy individuals as a control group. LN activity was evaluated by Renal SLEDAI (rSLEDAI), nephritis patients were divided into active lupus nephritis (renal SLEDAI≥4) and non-active lupus nephritis patients (renal SLEDAI = 0). Full history taking, clinical examination and baseline laboratory investigations were done for all participants. Total B lymphocytes and their subtypes Breg were measured by flow cytometry. Results: SLE diseased patients have significantly higher total B lymphocytes compared to matched controls; also, SLE diseased patients (LN and non-LN) have significantly lower CD19+ CD24 hi CD38 hi compared to matched controls, regardless of LN activity. Conclusion:The present study supports B cell and Breg role in aetio-pathogenesis of SLE and also contributes to the onset of LN which indicates a dysfunctional regulatory mechanism.

show abstract

“…Following immunosuppression in responders, Breg populations increased. In contrast, no noticeable change was seen in non-responders [19] .…”

Section: Discussionmentioning

confidence: 70%

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating CD19 CD24hi CD38hi Regulatory B Cells Percentage in Lupus Nephritis Patients: Does It Differ?

Fathi¹,

Gamal²,

Shawky³

et al. 2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

“…Patients with lupus nephritis had a significantly decreased in circulating IL-10+ Bregs levels compared to health controls ( 51 ). Patients with new-onset lupus nephritis had a decrease in CD19+CD5+CD1d high IL-10+ Bregs and restored Breg deficiency in patients who respond to immunosuppressive medications ( 48 ). The percentage of peripheral CD19+CD24 high CD27+ B cells with IL-10 and IL-35 production was low in patients with new-onset SLE ( 47 , 52 ).…”

Section: Imbalance Of Immune Regulatory Cells In Slementioning

confidence: 99%

Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus

Tsai,

Liao,

Hsiao

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical manifestations. Natural arising CD4+ regulatory T cells (Tregs) play a critical role in maintaining peripheral tolerance by suppressing inflammation and preventing autoimmune responses in SLE. Additionally, CD8+ regulatory T cells, type 1 regulatory T cells (Tr1), and B regulatory cells also have a less well-defined role in the pathogenesis of SLE. Elucidation of the roles of various Treg subsets dedicated to immune homeostasis will provide a novel therapeutic approach that governs immune tolerance for the remission of active lupus. Diminished interleukin (IL)-2 production is associated with a depleted Treg cell population, and its reversibility by IL-2 therapy provides important reasons for the treatment of lupus. This review focuses on the pathogenesis and new therapeutics of human Treg subsets and low-dose IL-2 therapy in clinical benefits with SLE.

show abstract

Regulatory B cells in autoimmune diseases: Insights and therapeutic potential

Su,

Jiang,

Song

et al. 2024

Journal of Autoimmunity

View full text Add to dashboard Cite

Regulatory B and T Cells and Their Association With Clinical Response in New-Onset Lupus Nephritis Patients

Abstract: Single-versus multiple-sample method to measure glomerular filtration rate.

Cited by 3 publications

References 9 publications

Circulating CD19 CD24hi CD38hi Regulatory B Cells Percentage in Lupus Nephritis Patients: Does It Differ?

Circulating CD19 CD24hi CD38hi Regulatory B Cells Percentage in Lupus Nephritis Patients: Does It Differ?

Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus

Regulatory B cells in autoimmune diseases: Insights and therapeutic potential

Contact Info

Product

Resources

About